Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIETTA Regimen for DLBCL with CNS Involvement
NCT02329080Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Dec 2014
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of rituximab, methotrexate, cytarabine, thiotepa, etoposide in diffuse large B-cell lymphoma (DLBCL), sponsored by International Extranodal Lymphoma Study Group. Started Dec 2014; status: completed.
02
Drugs
rituximabmethotrexatecytarabinethiotepaetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02329080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329080.